You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
This article has a correction. Please see:
Sigma-1 receptor subdues systemic inflammation
Systemic inflammation can be lethal, as in the case of septic shock. Rosen et al. hypothesized that the endoplasmic reticulum, now understood to affect inflammation, could be an untapped therapeutic target. They found that mice lacking the endoplasmic reticulum sigma-1 receptor had exacerbated responses to LPS or fecal slurry. The antidepressant fluvoxamine can bind sigma-1 and acts as an agonist. Therapeutic treatment of mice in the two inflammatory models revealed that fluvoxamine lowered inflammatory cytokine production and improved survival. Their results suggest that repurposing fluvoxamine to enhance sigma-1 activity may be beneficial for treating sepsis.
- Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.
